UO Ematologia e Trapianto Cellule Staminali, IRCCS, Centro di riferimento Oncologico di Basilicata
Welcome,         Profile    Billing    Logout  
 14 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Musto, Pellegrino
ERASMM, NCT06183489: Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Recruiting
2
50
Europe
Elranatamab
Stichting European Myeloma Network, Pfizer
Smoldering Multiple Myeloma
07/27
07/31
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting
N/A
190
Europe
acalabrutinib, Calquence
AstraZeneca, Yghea
Chronic Lymphocytic Leukemia
02/30
02/30

Download Options